<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02519075</url>
  </required_header>
  <id_info>
    <org_study_id>1386</org_study_id>
    <nct_id>NCT02519075</nct_id>
  </id_info>
  <brief_title>11C-Choline PET/CT and DWI MRI for Response Assessment of HCC Candidate to TARE</brief_title>
  <official_title>Diagnostic and Prognostic Role of 11C-Choline PET/CT and DWI MRI for Response Assessment in Patients Affected by Hepatocellular Carcinoma (HCC) and Candidate to TARE</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istituto Clinico Humanitas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Istituto Clinico Humanitas</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective exploratory study specifically investigating the diagnostic and predictive role&#xD;
      of 11C-Choline PET/CT and DWI MRI for response assessment in patients affected by HCC and&#xD;
      candidate to TARE. A minimum number of 20 patients will be considered for the analysis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      For the study, all patients with a histological diagnosis of HCC and eligible for TARE, i.e.&#xD;
      with liver predominant disease who are not eligible for curative surgery, after&#xD;
      multidisciplinary discussion will be included. In all cases, patients will undergo&#xD;
      11C-Choline PET/CT and DWI MRI before starting radioembolization and will be subsequently&#xD;
      restaged 3 months after treatment completion. A minimum number of 20 patients will be&#xD;
      considered for the analysis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2015</start_date>
  <completion_date type="Actual">December 2018</completion_date>
  <primary_completion_date type="Actual">December 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Variation of SUVmax (Maximal Standardized Uptake Value) in patients undergoing TARE for HCC</measure>
    <time_frame>Change from Baseline in SUVmax up to 3 months after TARE</time_frame>
  </primary_outcome>
  <enrollment type="Actual">14</enrollment>
  <condition>Hepatocarcinoma</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention</intervention_name>
    <description>Observational study</description>
  </intervention>
  <biospec_retention>None Retained</biospec_retention>
  <biospec_descr>
    <textblock>
      Biopsy specimen&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        All patients affected by HCC and referred to our Institution for TARE will be enrolled.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patients with a histological diagnosis of HCC and eligible for TARE, i.e. with liver&#xD;
             predominant disease who are not eligible for curative surgery, after multidisciplinary&#xD;
             discussion will be included;&#xD;
&#xD;
          -  obtained informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patients age &lt;18 years&#xD;
&#xD;
          -  pregnancy or breast-feeding;&#xD;
&#xD;
          -  patients affected by other malignancies within the last 3 years;&#xD;
&#xD;
          -  disseminated extrahepatic disease;&#xD;
&#xD;
          -  severely abnormal excretory liver function tests or ascites suggestive of liver&#xD;
             failure;&#xD;
&#xD;
          -  hepatopulmonary shunt &gt;20%;&#xD;
&#xD;
          -  vascular variants and abnormalities as demonstrated on pre-treatment angiography,&#xD;
             which cannot be corrected by embolisation and which lead to reflux of hepatic arterial&#xD;
             blood to the stomach, pancreas or bowel.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Egesta Lopci, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Humanitas Clinical and Research Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Istituto Clinico Humanitas</name>
      <address>
        <city>Rozzano</city>
        <state>Milano</state>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Lopci E, Torzilli G, Poretti D, de Neto LJ, Donadon M, Rimassa L, Lanza E, Sabongi JG, Ceriani R, Personeni N, Palmisano A, Pedicini V, Comito T, Scorsetti M, Chiti A. Diagnostic accuracy of ¹¹C-choline PET/CT in comparison with CT and/or MRI in patients with hepatocellular carcinoma. Eur J Nucl Med Mol Imaging. 2015 Aug;42(9):1399-407. doi: 10.1007/s00259-015-3079-5. Epub 2015 May 12.</citation>
    <PMID>25962590</PMID>
  </reference>
  <reference>
    <citation>Talbot JN, Gutman F, Fartoux L, Grange JD, Ganne N, Kerrou K, Grahek D, Montravers F, Poupon R, Rosmorduc O. PET/CT in patients with hepatocellular carcinoma using [(18)F]fluorocholine: preliminary comparison with [(18)F]FDG PET/CT. Eur J Nucl Med Mol Imaging. 2006 Nov;33(11):1285-9. Epub 2006 Jun 27.</citation>
    <PMID>16802155</PMID>
  </reference>
  <reference>
    <citation>Lanza E, Donadon M, Felisaz P, Mimmo A, Chiti A, Torzilli G, Balzarini L, Lopci E. Refining the management of patients with hepatocellular carcinoma integrating 11C-choline PET/CT scan into the multidisciplinary team discussion. Nucl Med Commun. 2017 Oct;38(10):826-836. doi: 10.1097/MNM.0000000000000719.</citation>
    <PMID>28723716</PMID>
  </reference>
  <reference>
    <citation>Castello, A., Lopci, E. Imaging HCC treated with radioembolization: review of the literature and clinical examples of choline PET utility. Clin Transl Imaging (2020). https://doi.org/10.1007/s40336-020-00384-y</citation>
  </reference>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>June 26, 2015</study_first_submitted>
  <study_first_submitted_qc>August 7, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 10, 2015</study_first_posted>
  <last_update_submitted>September 29, 2020</last_update_submitted>
  <last_update_submitted_qc>September 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatocarcinoma</keyword>
  <keyword>TARE</keyword>
  <keyword>response assessment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

